DDInter119 DDInter7
Armodafinil is the enantiopure of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or shift work disorder (SWD). Research has shown that armodafinil significantly improves driving simulator performance in patients with SWD. Armodafinil consists of the (−)-R-enantiomer of the racemic modafinil. Armodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. Food and Drug Administration (FDA) in June 2007.
Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed after unsuccessful endocrine therapy. It is either given alone in patients who has undergone endocrine therapy and chemotherapy after the metastasis of cancer, or in combination with . Following oral treatment in patients with HR-positive, HER2-negative breast cancer, abemaciclib demonstrated increased progression-free survival rates and objective response rates. Abemaciclib has been used in trials studying the treatment of melanoma, lymphoma, neoplasm, solid tumor, and glioblastoma.
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secobarbital
Abemaciclib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Troleandomycin
Abemaciclib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Abemaciclib may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib
Abemaciclib may lead to a major life threatening interaction when taken with Troleandomycin
Abemaciclib may lead to a major life threatening interaction when taken with Fingolimod